Why this drug is interesting

Dobutamine is the drug that clarifies the difference between an inotrope and a vasopressor, and clinicians who conflate the two get into trouble with it. Noradrenaline raises blood pressure by constricting vessels. Dobutamine raises cardiac output by making the heart contract harder — and, through β₂ stimulation, simultaneously dilates vessels.

The net effect on blood pressure is therefore unpredictable. In a patient whose problem is genuinely pump failure with high filling pressures, improved output more than compensates and the pressure rises. In a patient who is under-filled, or whose shock is distributive rather than cardiogenic, the vasodilatation dominates and the pressure falls. The SmPC records that precipitous decreases in blood pressure have occasionally been described.¹

Pharmacology

Mechanism

Dobutamine is a synthetic catecholamine acting predominantly at β₁ adrenoceptors, with weaker β₂ and α₁ activity.

Receptor	Effect	Net result
β₁	Increased contractility and, to a lesser degree, heart rate	Increased stroke volume and cardiac output
β₂	Peripheral vasodilatation	Reduced systemic vascular resistance — afterload falls, but so may blood pressure
α₁	Mild vasoconstriction	Partly offsets the β₂ effect

Kinetics

Onset: Within 1–2 minutes of starting the infusion
Half-life: 2–3 minutes
Steady state: Reached in roughly 10 minutes
Metabolism: COMT and conjugation; no active metabolites of significance
Implication: Titratable minute-to-minute, and rapidly reversible on stopping — a genuine safety advantage

Indications and dosing

Licensed indications

Positive inotropic support in the treatment of cardiac decompensation due to depressed contractility, from organic heart disease or following cardiac surgery — especially where low cardiac output is associated with raised pulmonary capillary pressure¹
May be added to dopamine in cardiogenic or septic shock
Detection of myocardial ischaemia by stress echocardiography
Paediatric inotropic support in low cardiac output states, from neonates to 18 years

Dosing

The majority of patients respond to 2.5–10 micrograms/kg/min¹
In individual cases doses up to 40 micrograms/kg/min have been given
Must be diluted and given by continuous intravenous infusion, individually titrated to response
Paediatric dilution: 0.5–1 mg/mL (maximum 5 mg/mL if fluid-restricted) in glucose 5% or sodium chloride 0.9%

Monitoring

Continuous ECG and blood pressure monitoring are essential, ideally with invasive arterial monitoring. Watch heart rate closely: a substantial rise indicates the dose is doing more harm than good in a patient with coronary disease.

Contraindications and cautions

Contraindications

Hypersensitivity to dobutamine or excipients — including sulfite-sensitive asthmatics
Mechanical obstruction of ventricular filling and/or outflow — pericardial tamponade, hypertrophic obstructive cardiomyopathy, severe aortic stenosis. Constrictive pericarditis falls within the same category
Hypovolaemic conditions — note this is a stated contraindication, not merely something to correct first
Phaeochromocytoma

Key warnings

Coronary disease may deteriorate, particularly if therapy is accompanied by a considerable rise in heart rate or blood pressure¹
Tolerance may develop after more than 72 hours of continuous use — receptor downregulation
Caution in acute heart failure generally, because of arrhythmia risk and uncertainty about long-term effects on myocardial dysfunction¹
Blood pressure and heart rate effects can be pronounced in children
Hypokalaemia may occur

Stress echocardiography

Used as a pharmacological stressor to detect inducible ischaemia. The contraindication list for this indication is much longer and includes recent myocardial infarction within 30 days, unstable angina, left main stem stenosis, significant outflow obstruction or valvular disease, severe heart failure (NYHA III–IV), significant arrhythmia or conduction disturbance, acute pericarditis, myocarditis or endocarditis, aortic dissection or aneurysm, and uncontrolled hypertension.¹ This is a cardiology-supervised procedure, not an emergency department one.

Adverse effects and practical use

Adverse effects

Tachycardia — dose-related and the commonest limiting effect
Arrhythmia, including ventricular ectopy and sustained arrhythmia
Hypotension — the counterintuitive one, from β₂ vasodilatation
Hypertension, in some patients
Angina and myocardial ischaemia — increased oxygen demand
Palpitations, headache, nausea, tremor
Phlebitis at the infusion site; hypokalaemia

Combining with a vasopressor

In cardiogenic shock, dobutamine is frequently paired with noradrenaline: the inotrope supplies output while the vasopressor maintains perfusion pressure against the β₂-mediated vasodilatation. That combination is standard critical care practice and should be a planned decision, made with critical care involvement, rather than an escalation improvised in the department.

Critical appraisal

Inotropes improve haemodynamics without clear evidence of improved survival, and this is the central honest point about dobutamine. It reliably raises cardiac output; that this translates into better patient outcomes in cardiogenic shock or decompensated heart failure has not been convincingly demonstrated. The SmPC's own caution about "uncertainty about long term effects on myocardial dysfunction" reflects this.
There is a plausible mechanism for harm. Increasing contractility in a failing, often ischaemic ventricle raises oxygen demand and arrhythmia risk. Observational data have associated inotrope use in acute heart failure with worse outcomes, though confounding by indication is severe — sicker patients get inotropes.
Dobutamine versus levosimendan or milrinone is not settled, and choice is largely driven by local practice, cost and availability rather than by strong comparative evidence.
Its use in septic shock is limited and specific, for the subgroup with genuine myocardial dysfunction and persistent hypoperfusion despite adequate filling and vasopressor support — not as a routine addition.
Stress echocardiography is a well-validated use and is the one indication where the evidence base is unambiguous — a reminder that a drug's uses can differ greatly in how well they are supported.

References

1
Dobutamine 12.5 mg/ml concentrate for solution for infusion — Summary of Product Characteristics. electronic Medicines Compendium. Sections 4.1–4.4, 5.2. Verified 20 Aug 2026.
2
Dobutamine — dosing and safety monograph. BNF, NICE. bnf.nice.org.uk
3
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42(36):3599–3726.
4
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 2021;49(11):e1063–143.
5
Léopold V, Gayat E, Pirracchio R, et al. Catecholamines in cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med 2018;44(6):847–56.
6
NICE NG106. Chronic heart failure in adults: diagnosis and management. National Institute for Health and Care Excellence.

Dobutamine

At a glance